###begin article-title 0
The Integrin Antagonist Cilengitide Activates alphaVbeta3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: GCA CR. Performed the experiments: GCA LP. Analyzed the data: GCA LP CR. Wrote the paper: GCA CR.
###end p 1
###begin p 2
###xml 793 796 745 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 802 809 754 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576/577</sup>
###xml 818 821 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">418</sup>
###xml 841 844 793 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 850 853 802 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 591 596 <span type="species:ncbi:9606">human</span>
Cilengitide is a high-affinity cyclic pentapeptdic alphaV integrin antagonist previously reported to suppress angiogenesis by inducing anoikis of endothelial cells adhering through alphaVbeta3/alphaVbeta5 integrins. Angiogenic endothelial cells express multiple integrins, in particular those of the beta1 family, and little is known on the effect of cilengitide on endothelial cells expressing alphaVbeta3 but adhering through beta1 integrins. Through morphological, biochemical, pharmacological and functional approaches we investigated the effect of cilengitide on alphaVbeta3-expressing human umbilical vein endothelial cells (HUVEC) cultured on the beta1 ligands fibronectin and collagen I. We show that cilengitide activated cell surface alphaVbeta3, stimulated phosphorylation of FAK (Y397 and Y576/577), Src (S418) and VE-cadherin (Y658 and Y731), redistributed alphaVbeta3 at the cell periphery, caused disappearance of VE-cadherin from cellular junctions, increased the permeability of HUVEC monolayers and detached HUVEC adhering on low-density beta1 integrin ligands. Pharmacological inhibition of Src kinase activity fully prevented cilengitide-induced phosphorylation of Src, FAK and VE-cadherin, and redistribution of alphaVbeta3 and VE-cadherin and partially prevented increased permeability, but did not prevent HUVEC detachment from low-density matrices. Taken together, these observations reveal a previously unreported effect of cilengitide on endothelial cells namely its ability to elicit signaling events disrupting VE-cadherin localization at cellular contacts and to increase endothelial monolayer permeability. These effects are potentially relevant to the clinical use of cilengitide as anticancer agent.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hynes1">[1]</xref>
###xml 651 654 644 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hynes2">[2]</xref>
###xml 897 900 890 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hynes2">[2]</xref>
###xml 1249 1252 1242 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hynes2">[2]</xref>
Endothelial cell - matrix interactions mediated by integrin adhesion receptors play a critical role in vascular development, angiogenesis and vascular homeostasis [1]. Integrins are heterodimeric cell surface complexes formed by non-covalently associated alpha and beta subunits, consisting of large extracellular domains, single transmembrane spanning domains and short cytoplasmic tails. A particular feature of integrins is their tight regulation of ligand binding activity. Transition from a low to a high affinity state ("affinity maturation") can be induced by intracellular signaling events ("inside-out" signaling) or by high-affinity ligands [2]. Ligand binding induces allosteric changes in the receptor conformation, leading to the activation of intracellular signaling pathways, including the Ras-MAPK, PI3K-PKB-mTOR and small GTPases (e.g. Rho, Rac) pathways ("outside-in" signaling) [2]. Since integrins do not possess intrinsic enzymatic activities they require interaction with cytoplasmic adaptor molecules and kinases, including FAK and Src-family kinases, to transduce signaling events. Integrin-mediated signaling is critical for the stabilization of cell adhesion and the promotion of cell migration, proliferation and survival [2].
###end p 4
###begin p 5
###xml 274 277 267 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
###xml 493 496 472 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Kumar1">[4]</xref>
###xml 510 513 489 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Smith1">[5]</xref>
###xml 617 619 589 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 693 696 651 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dechantsreiter1">[6]</xref>
###xml 742 750 700 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 750 753 708 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Nisato1">[7]</xref>
###xml 758 765 716 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 765 768 723 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Buerkle1">[8]</xref>
###xml 769 773 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Loges1">[10]</xref>
###xml 850 853 808 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Buerkle1">[8]</xref>
###xml 855 858 813 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Yamada1">[9]</xref>
###xml 860 864 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Mitjans1">[11]</xref>
###xml 866 870 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-MacDonald1">[12]</xref>
###xml 924 932 882 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 932 936 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Bieler1">[13]</xref>
###xml 984 988 942 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Tentori1">[14]</xref>
###xml 1006 1010 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Albert1">[15]</xref>
###xml 1010 1017 968 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1117 1121 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hariharan1">[16]</xref>
###xml 1197 1201 1155 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Nabors1">[17]</xref>
###xml 1203 1207 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Reardon1">[18]</xref>
###xml 1293 1297 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Friess1">[19]</xref>
###xml 1346 1350 1304 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Raguse1">[20]</xref>
###xml 1461 1465 1419 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Stupp1">[21]</xref>
###xml 1165 1173 <span type="species:ncbi:9606">patients</span>
Integrin alphaVbeta3 is expressed at low levels on quiescent endothelial cells, while it is strongly induced on angiogenic endothelial cells present in granulation tissue and cancer, and is considered as an attractive therapeutic target to inhibit pathological angiogenesis [3]. Pharmacological inhibition of alphaVbeta3 suppresses angiogenesis in many experimental models and alphaVbeta3 antagonists (i.e. antibodies, peptides and peptidomimetics) are being developed as antiangiogenic drugs [4]. Cilengitide [5] (EMD121974) is a cyclic Arg-Gly-Asp (RGD)-derived peptide binding with high affinity to alphaVbeta3 (IC50 of 0.6 nM) and inhibiting alphaVbeta3 and alphaVbeta5-dependent adhesion [6]. Cilengitide displays antiangiogenic effects in vitro[7] and in vivo[8]-[10]. It exerts antitumor effects against experimental melanoma and brain tumors [8], [9], [11], [12], it sensitizes endothelial cells to TNF cytotoxicity in vitro[13] and enhances antitumor effects of chemotherapy [14] and radiotherapy [15]in vivo. Cilengitide is in clinical development as anticancer drug. As a single agent it is well-tolerated [16] and shows evidence of durable responses in patients with recurrent gliomas [17], [18]. In combination with chemotherapy it showed evidence of activity in pancreas cancers [19] and in highly vascularized head and neck tumors [20]. Cilengitide is now in phase III clinical testing in glioblastoma in combination with radio- and chemotherapy [21].
###end p 5
###begin p 6
###xml 253 256 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Nisato1">[7]</xref>
###xml 258 262 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Brooks1">[22]</xref>
###xml 493 496 433 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
It is generally assumed that the antiangiogenic activity of cilengitide is due to the inhibition of sprouting and differentiation and the induction of anoikis of angiogenic endothelial cells relaying on alphaVbeta3/alphaVbeta5 for adhesion and survival [7], [22]. However, in addition to alphaV integrins, angiogenic endothelial cells express multiple integrins, including alpha1beta1, alpha2beta1, alpha4beta1, alpha5beta1, alpha6beta1, and alpha6beta4, which are not targeted by cilengitide [3]. Adhesion through these integrins might compromise the antiangiogenic activity of cilengitide. Little is known on the effect of cilengitide on endothelial cells expressing alphaVbeta3/alphaVbeta5 but adhering mostly through other integrins, in particular those of the beta1 family.
###end p 6
###begin p 7
To address this question, we examined the effect of cilengitide on HUVEC, which express alphaVbeta3, under condition of beta1 integrin-mediated adhesion. Here we demonstrate that HUVEC exposure to cilengitide results in the phosphorylation of Src, FAK and VE-cadherin, the accumulation of alphaVbeta3 at the cell edge, the disappearance of VE-cadherin from cell-cell contacts and the increase in HUVEC monolayer permeability.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
Cilengitide causes disappearance of alphaVbeta3 from focal adhesions and promotes its accumulation at the cell periphery
###end title 9
###begin p 10
###xml 176 180 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Bieler1">[13]</xref>
###xml 514 518 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Zaric1">[23]</xref>
###xml 630 634 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Nabors1">[17]</xref>
###xml 928 932 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dormond1">[24]</xref>
###xml 1138 1146 1051 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g001">Figure 1</xref>
###xml 1475 1483 1375 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g001">Figure 1</xref>
Cilengitide efficiently inhibits alphaVbeta3-mediated cell adhesion and induces detachment of endothelial cells cultured on alphaVbeta3 ligands, such as vitronectin or gelatin [13]. To test the effect of cilengitide on endothelial cells expressing alphaVbeta3 but mostly using beta1 integrins for their adhesion, we seeded HUVEC on fibronectin and collagen I. HUVEC use predominantly alpha5beta1 to adhere to fibronectin (with minor contribution of alphaVbeta3) and alpha1beta1/alpha2beta1 to adhere to collagen I [23]. Subsequently we exposed adherent HUVEC to cilengitide at a clinically-relevant concentration (i.e. 10 microM, [17]) or EMD135981, an Arg-Ala-Asp (RAD)-based inactive cyclopeptide. First we monitored the effect of cilengitide on alphaVbeta3 localization. In HUVEC plated on fibronectin, alphaVbeta3 was present at focal adhesions while beta1 integrins clustered at fibrillar adhesions, as previously observed [24]. Cilengitide, but not EMD135981, caused loss of alphaVbeta3 from paxillin-positive focal adhesions and promoted the appearance of thin, alphaVbeta3-positive and paxillin negative linings at the cell edge (Figure 1, arrows). The localization of beta1 integrins at fibrillar adhesions was not perturbed by cilengitide. HUVEC cultured on collagen I showed fewer focal adhesions while had well-developed fibrillar adhesions. Cilengitide treatment induced alphaVbeta3 accumulation at the cell border without affecting beta1 integrin localization (Figure 1).
###end p 10
###begin title 11
Cilengitide causes loss of alphaVbeta3 from focal adhesions and promotes appearance of alphaVbeta3 patches at the cell edge.
###end title 11
###begin p 12
HUVEC were plated on coverslips coated with fibronectin or collagen I and were treated with 10 microM of cilengitide for 20 minutes. The localization of the alphaVbeta3 or beta1 integrin (green) and paxillin (red) were monitored by immunofluorescence staining. In HUVEC plated on fibronectin alphaVbeta3 was present at focal adhesions, while beta1 was present at fibrillar adhesions. Cilengitide, but not EMD 135981, caused loss of alphaVbeta3 from focal adhesions and appearance of alphaVbeta3-positive thin patches at the cell edge (arrows). beta1 localization was not altered by cilengitide. A similar effect on alphaVbeta3 (arrows) was observed on cells plated on collagen I, with the difference that focal adhesions were less abundant on this matrix. Optical magnification: 400x; Bar: 10 microm. (n = 5).
###end p 12
###begin title 13
Cilengitide causes VE-cadherin disappearance from cellular junctions
###end title 13
###begin p 14
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dejana1">[25]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Wang1">[26]</xref>
###xml 533 542 526 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2a</xref>
###xml 785 794 778 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2a</xref>
###xml 830 834 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Kevil1">[27]</xref>
###xml 250 256 <span type="species:ncbi:9913">bovine</span>
VE-cadherin is a major endothelial cell junctional molecule mediating cell-cell adhesion [25]. It has been previously reported that integrin ligation through multivalent fibronectin-coated beads disrupted VE-cadherin-containing adherens junctions in bovine aortic endothelial cells [26]. We therefore tested, whether alphaVbeta3 ligation by monovalent cilengitide affected VE-cadherin localization. In confluent monolayers of HUVEC cultured for 18 hours on fibronectin or collagen I, VE-cadherin was localized at cell-cell contacts (Figure 2a and data not shown). Addition of cilengitide markedly disrupted VE-cadherin localization at cellular junctions, while the EMD135981 peptide was ineffective. Stimulation with VEGF also caused VE-cadherin disappearance from cellular junctions (Figure 2a), consistent with previous reports [27].
###end p 14
###begin title 15
Cilengitide induces VE-cadherin loss form cellular junctions.
###end title 15
###begin p 16
(a) Confluent HUVEC plated on fibronectin, were exposed to cilengitide or EMD135981 (10 microM each) or VEGF (100 ng/ml) for 20 minutes and stained for VE-cadherin. Cilengitide and VEGF treatments disrupted VE-cadherin localization at cellular junctions, while EMD135981 showed no effect (n = 3). Optical magnification: 400x; Bar: 10 microm. (b) Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 microM each) for the indicated time and double stained for VE-cadherin and beta3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of beta3 at VE-cadherin-depleted cell-cell borders (arrows). Paralleling loss of VE-cadherin from cell-cell junctions, 'gaps' appeared in the monolayer (asterisks). (n = 4). Optical magnification: 400x; Bar: 10 microm. (c) Higher magnification (2x zooming in) of HUVEC cultures of the experiment shown in panel b to demonstrate rare co-localization of VE-cadherin and beta3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). (n = 4). Bars: 10 microm.
###end p 16
###begin p 17
###xml 367 376 346 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2b</xref>
###xml 580 589 552 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2b</xref>
###xml 697 706 669 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2b</xref>
###xml 887 896 852 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g002">Figure 2c</xref>
Next, we performed alphaVbeta3 and VE-cadherin co-staining experiments to monitor the spatial relationship between the appearance of alphaVbeta3 at the cell periphery and loss of VE cadherin from cell-cell junctions. In confluent HUVEC cultures VE-cadherin and alphaVbeta3 were localized at different locations (cell-cell contacts and focal adhesions, respectively) (Figure 2b, control). Upon stimulation with cilengitide, VE-cadherin staining became discontinuous and alphaVbeta3 appeared at cell borders, typically at sites where VE-cadherin disappeared from cellular contacts (Figure 2b, time course). Paralleling loss of VE-cadherin from cell-cell junctions, 'gaps' appeared in the monolayer (Figure 2b, asterisks), consistent with diminished cell-cell adhesion and cell retraction. Concomitant presence of VE-cadherin and alphaVbeta3 at cell-cell contacts was very rarely observed (Figure 2c, arrowheads), suggesting that co-localization of alphaVbeta3 and VE-cadherin is a rather mutually exclusive event.
###end p 17
###begin p 18
Taken together, these results indicate that exposure of confluent HUVEC to cilengitide while cultured on fibronectin or collagen I, resulted in the redistribution of alphaVbeta3 from focal adhesions to the cell periphery and the concomitant disappearance of VE-cadherin from cellular junctions.
###end p 18
###begin title 19
Cilengitide activates cell surface alphaVbeta3 integrin
###end title 19
###begin p 20
###xml 423 427 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Frelinger1">[28]</xref>
###xml 429 433 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Khaspekova1">[29]</xref>
###xml 619 628 588 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g003">Figure 3a</xref>
###xml 647 648 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 767 771 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dormond1">[24]</xref>
###xml 1029 1030 995 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1233 1242 1192 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g003">Figure 3b</xref>
###xml 1389 1398 1348 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g003">Figure 3b</xref>
###xml 1428 1429 1387 1388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1547 1551 1499 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dormond1">[24]</xref>
The disappearance of VE-cadherin from cell-cell contacts suggested that cilengitide-bound integrin alphaVbeta3 might initiate intracellular signaling events by activating alphaVbeta3. To test this hypothesis we monitored the capacity of cilengitide to induce affinity maturation of alphaVbeta3 on endothelial cells using antibodies (i.e. LIBS-1 and CRC54) recognizing ligand-induced binding sites (LIBS) on beta3 integrins [28], [29]. Cilengitide, but not EMD135981, induced LIBS-1 and CRC54 epitope expression on HUVEC in suspension, without altering total cell surface levels of alphaVbeta3 as detected by LM609 mAb (Figure 3a). Addition of MnCl2, a known integrin activator, also induced LIBS-1 and CRC54 epitope expression (data not shown) as previously reported [24]. Cilengitide had no effect on beta1 LIBS expression as detected by mAb HUTS-21 (data not shown). To test whether cilengitide-induced affinity maturation also occurred on adherent HUVEC, we exposed fibronectin-adherent HUVEC to cilengitide, EMD135981 or MnCl2 and stained them with CRC54 (LIBS-1 mAb does not work on fixed cells) and LM609. In unstimulated HUVEC, focal adhesions were positive for CRC54, consistent with the ligated/active state of alphaVbeta3 (Figure 3b). Upon cilengitide stimulation we observed CRC54-positive patches at the cell periphery, consistent with a cilengitide-ligated (activated) state (Figure 3b, arrows). In comparison, MnCl2 treatment enhanced alphaVbeta3 clustering and expression of the CRC54 epitope at focal adhesions as already reported [24].
###end p 20
###begin title 21
Cilengitide activates alphaVbeta3 on HUVEC.
###end title 21
###begin p 22
###xml 589 590 564 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 987 988 928 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
(a) HUVEC in suspension were exposed to 10 microM of cilengitide or EMD135981 for 10 minutes, stained by immunofluorescence for beta3 LIBS and total alphaVbeta3 expression (with LIBS-1 and LM609 mAbs, respectively) and analyzed by flow cytometry. Cilengitide, but not EMD135981, induced LIBS expression (left histograms, thick lines), without affecting total alphaVbeta3 expression (right histograms, thick lines). Dotted lines: cellular fluorescence in the absence of primary antibody. (n = 3). (b) Fibronectin-adherent HUVEC were exposed to 10 microM cilengitide, EMD135981, or 1 mM MnCl2 for 10 minutes, stained for beta3 LIBS and total alphaVbeta3 expression (with CRC54 or LM609 mAbs, respectively) and analyzed by immunofluorescence microscopy. Total alphaVbeta3 and beta3 LIBS were present at focal adhesions in unstimulated HUVEC and at tiny patches at the cell edge in cilengitide-exposed HUVEC, thus confirming that alphaVbeta3-positive patches contain active alphaVbeta3. MnCl2 stimulated recruitment and activation of alphaVbeta3 at focal adhesions. (n = 2). Optical magnification: 400x; Bars: 10 microm.
###end p 22
###begin title 23
Cilengitide induces Src and FAK phosphorylation
###end title 23
###begin p 24
###xml 217 220 217 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Hynes2">[2]</xref>
###xml 222 225 222 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
###xml 356 359 356 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Xu1">[30]</xref>
###xml 663 666 659 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 714 717 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 736 740 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Playford1">[31]</xref>
###xml 903 906 899 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 946 949 942 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 951 960 947 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g004">Figure 4a</xref>
###xml 1068 1071 1064 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576</sup>
###xml 1077 1080 1073 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">577</sup>
###xml 1134 1138 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Calalb1">[32]</xref>
###xml 1192 1201 1188 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g004">Figure 4b</xref>
###xml 1238 1242 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Missbach1">[33]</xref>
###xml 1255 1258 1251 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 1268 1271 1264 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576</sup>
###xml 1293 1309 1289 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g004">Figure 4a and 4b</xref>
###xml 363 368 <span type="species:ncbi:9606">human</span>
Next we sought after evidence for cilengitide-induced intracellular signaling events. Src-dependent phosphorylation of focal adhesion kinase (FAK) is one of the first signaling events initiated by integrin activation [2], [3]. Src, like other Src family kinases, is negatively regulated though the phosphorylation of a carboxyl-terminal tyrosine residue (Y529 in human Src). This phosphorylation forces the Src C-terminal domain to interact with the SH2 and SH3 domains, thus forming a loop that masks the Src kinase domain [30]. Disruption of this loop, achieved through protein tyrosine phosphatases (i.e. PTPalpha, PTPIB, Shp2) -mediated dephosphorylation of Y529, or via integrin clustering in the absence of Y529 dephosphorylation [31], allows Src to interact with its substrates via SH2 and SH3 domains. Cilengitide treatment of confluent HUVEC, increased Src phosphorylation of tyrosine residue Y419 without decreasing phosphorylation of Y529 (Figure 4a), consistent with integrin-mediated Src activation, and promoted FAK phosphorylation at tyrosine residues Y576 and Y577, two well-characterized phosphoacceptor sites of Src [32], relative to non-treated or EMD135981-treated cells (Figure 4b). The Src kinase inhibitor CGP77675 [33] suppressed Y419 Src and Y576 FAK phosphorylation (Figure 4a and 4b).
###end p 24
###begin title 25
Cilengitide induces Src and FAK phosphorylation.
###end title 25
###begin p 26
###xml 57 60 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 270 273 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 293 296 285 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 334 337 326 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 453 456 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 462 465 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576</sup>
(a) Western blotting analysis of Src phosphorylation at Y529 and Y419 and total Src in HUVEC grown on fibronectin and exposed for 10 minutes to EMD135981, cilengitide (10 microM each) and CGP77675 (2.5 microM) as indicated. Cilengitide increased Src phosphorylation at Y419 but did not alter Y529 phosphorylation. CGP77675 prevented Y419 phosphorylation. (b) Western blotting analysis of the same cells as in panel a, but for phosphorylation of FAK at Y397 and Y576 and total FAK. Cilengitide increased FAK phosphorylation at both tyrosine residues and this was inhibited by CGP77675. EMD135981 had no effect on Src or FAK phosphorylation. Actin was detected to demonstrate equal loading of the lanes. The bar graph represents the relative level of phospho Src/FAK over total Src/FAK as determined by band density analysis. (n = 3).
###end p 26
###begin title 27
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 70 73 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
Cilengitide induces VE-cadherin phosphorylation at residues Y658 and Y731
###end title 27
###begin p 28
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Wallez1">[34]</xref>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 400 404 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Potter1">[35]</xref>
###xml 521 530 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g005">Figure 5a</xref>
###xml 572 575 565 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 616 619 609 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 781 790 770 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g005">Figure 5b</xref>
###xml 1259 1267 1234 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g006">Figure 6</xref>
Src was shown to phosphorylate the VE-cadherin cytoplasmic domain in response to VEGF stimulation [34]. We therefore tested whether cilengitide induced Src activation resulted in the phosphorylation of the VE-cadherin cytoplasmic domain. Cilengitide treatment induced VE-cadherin phosphorylation at Y658 and Y731, which correspond to the binding sites for p120 catenin and beta-catenin, respectively [35]. Addition of CGP77675 (2.5 microM) strongly reduced basal and cilengitide-induced phosphorylation of both residues (Figure 5a). As reported, VEGF stimulation induced Y658 phosphorylation and to a lesser extent Y731 phosphorylation, which were also inhibited by CGP77675. In contrast to VEGF, however, cilengitide did not induce phosphorylation of MEK 1/2, Akt, and Ikappa-B, (Figure 5b and data not shown). Next we tested the effect of inhibition of Src kinase activity on the recruitment of alphaVbeta3 to the cell periphery and the disappearance of VE-cadherin from cell junctions. Indeed, CGP77675 prevented the formation of alphaVbeta3 patches at the cell edge in HUVEC plated on fibronectin or collagen I at both sub-confluent and confluent conditions, and attenuated the disappearance of VE-cadherin from cell-cell contacts induced by cilengitide (Figure 6).
###end p 28
###begin title 29
Cilengitide induces Src-dependent phosphorylation of VE-cadherin cytoplasmic domain.
###end title 29
###begin p 30
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 345 348 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 354 357 350 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 380 383 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
(a) Western blotting analysis of VE-cadherin phosphorylation at tyrosine residues Y658 and Y731 and total VE-cadherin in HUVEC grown on fibronectin or collagen I and stimulated for 10 minutes with cilengitide (10 microM) or VEGF (100 ng/ml) in the presence or absence of CGP77675. Cilengitide treatment increased VE-cadherin phosphorylation at Y658 and Y731, while VEGF enhanced Y658 phosphorylation only. The bar graph represents the relative level of phospho VE-cadherin over total VE-cadherin as determined by band density analysis. (b) Western blotting analysis of phospho and total ERK 1/2 of the same cultures as in panel a. VEGF activated ERK 1/2, while cilengitide did not. Actin was detected to demonstrate equal loading of the lanes. (n = 3).
###end p 30
###begin title 31
Src inhibition prevents cilengitide-induced relocalization of alphaVbeta3 at the cell edge and disappearance of VE-cadherin from cellular junctions.
###end title 31
###begin p 32
###xml 677 680 655 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 739 759 717 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">material and methods</xref>
(a) Subconfluent and confluent HUVEC cultured on fibronectin or collagen I were exposed for 20 minutes to cilengitide (10 microM) in the presence of absence of CGP77675 (2.5 microM) and stained for alphaVbeta3. Cilengitide-induced recruitment of alphaVbeta3 to the cell edge (arrows) and this was prevented by CGP77675. (b) Confluent HUVEC cultured on fibronectin were treated for 20 minutes with cilengitide in the presence or absence of CGP77675. CGP77675 prevented cilengitide-induced VE-cadherin loss from cell-cell contacts. The bar graph gives the quantification of VE-cadherin staining at cell borders. The white and gray segments of the bars represent absent/disrupted vs. strong/continuous VE-cadherin staining, respectively (see material and methods for details). (n = 3). Optical magnification: 400x; Bars: 10 microM.
###end p 32
###begin p 33
Taken together these results establish that cilengitide induces alphaVbeta3 affinity maturation, and initiates signaling events in endothelial cells leading to phosphorylation of Src, FAK and VE-cadherin. These phosphorylation events, recruitment of alphaVbeta3 at the cell periphery and disappearance of VE-cadherin from cellular contacts requires Src kinase activity.
###end p 33
###begin title 34
Cilengitide enhances HUVEC monolayer permeability
###end title 34
###begin p 35
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Dejana2">[36]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Ruegg1">[37]</xref>
###xml 462 471 458 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g007">Figure 7a</xref>
###xml 760 769 756 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g007">Figure 7b</xref>
###xml 934 950 926 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g007">Figure 7a and 7b</xref>
VE-cadherin-mediated cell-cell adhesion and integrin-mediated cell-matrix adhesion are essential for maintaining endothelial cell monolayer tightness [36], [37]. Based on the above observations, we set up to test whether cilengitide treatment increased permeability of confluent HUVEC. Addition of cilengitide (10 microM) to HUVEC cultured on fibronectin or collagen-coated filter inserts, resulted in a time-dependent increase in transendothelial permeability (Figure 7a). Microscopic examination of the filters at the end of the assay (240 minutes) revealed that cilengitide induced morphological changes to the cultures, in particular the appearance of dark (dense) dendritic-like cells, consistent with cells that retracted or detached from the substrate (Figure 7b, arrows). CGP77675 (2.5 microM) partially abolished cilengitide-induced increased permeability but was ineffective in preventing the appearance of retracted cells (Figure 7a and 7b). As expected treatment of HUVEC cultured on vitronectin-coated filters resulted in massive cell detachment and increased permeability, consistent with alphaVbeta3/alphaVbeta5-mediated adhesion to this substrate (data not shown).
###end p 35
###begin title 36
Cilengitide augments the permeability of HUVEC monolayers.
###end title 36
###begin p 37
(a). HUVEC were grown on fibronectin- or collagen I-coated PET filter inserts for 20 hours to ensure confluence and treated with cilengitide (10 microM), CGP77675 (2.5 microM) or a combination thereof. Permeability was measured using the tracer molecule FITC-dextran. Cilengitide increased HUVEC monolayer permeability on both matrices and CGP77675 only partially prevented this increase. Results represent the increase in permeability of treated cultures relative to untreated controls at t = 0 and is given in arbitrary fluorescence units (AU). (b) Crystal violet staining of control and treated filters at the end of the assay (240 minutes) revealed that cilengitide did not cause extensive detachment of HUVEC but induced the appearance of retraced, dendritic-like cells (arrows). (Triplicate filters/condition, n = 3).
###end p 37
###begin title 38
Cilengitide interferes with beta1 integrin-dependent HUVEC attachment on low-density ligands
###end title 38
###begin p 39
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-DiazGonzalez1">[38]</xref>
###xml 855 859 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Calderwood1">[39]</xref>
###xml 912 914 868 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 1278 1287 1214 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g008">Figure 8a</xref>
###xml 1483 1492 1416 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g008">Figure 8a</xref>
###xml 1903 1912 1836 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g008">Figure 8b</xref>
###xml 2081 2090 2014 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g008">Figure 8c</xref>
###xml 2350 2357 2283 2290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004449-t001">Table 1</xref>
###xml 2359 2363 2292 2296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Maubant1">[40]</xref>
The appearance of retracted HUVEC in cilengitide-treated filter inserts during the permeability assays on fibronectin and collagen I, suggested the possibility that cilengitide might interfere with adhesion on fibronectin or collagen I. Activation of one individual integrin was previously shown to interfere with the function of other integrins though a transdominant negative effect [38]. To test whether cilengitide-induced alphaVbeta3 activation might interfere with beta1 integrin-mediated adhesion, we first performed short-term adhesion assays on vitronectin (as alphaVbeta3 ligand), fibronectin (as mixed alpha5beta1>alphaVbeta3 ligand) or collagen I (as beta1 ligand). Since the transdominant negative effect is based on the competition for intracellular adaptor and signaling molecules among unclasped cytoplasmic beta tails of active integrins [39], and the stoechiometry of active (i.e. alphaVbeta3) vs target (i.e. beta1) integrins is critical, we tested the effect of cilengitide on HUVEC engaging decreasing levels of beta1 integrins by coating decreasing concentrations of ligands. Cilengitide prevented alphaVbeta3-mediated HUVEC adhesion to vitronectin at any coating concentrations, consistent with a direct inhibition of alphaVbeta3 ligand binding activity (Figure 8a). Cilengitide showed no effect on beta1-mediated HUVEC adhesion on fibronectin and collagen I coated at high concentrations, while it interfered with HUVEC adhesion to low ligand concentrations (Figure 8a). To test the effects of cilengitide on cells already attached, we added cilengitide to HUVEC cultured for 18 hours in wells coated with graded amounts of vitronectin, fibronectin or collagen I. Cilengitide induced detachment of HUVEC cultured on vitronectin regardless of the coating concentration, while it detached HUVEC from fibronectin and collagen I only in wells coated with low protein concentrations (Figure 8b). Addition of CGP77675 did not abolish the anti-adhesive effect of cilengitide on HUVEC plated on low-density fibronectin or collagen I in a short-term adhesion assay (Figure 8c). Sub G1 DNA content analysis of control and treated cultures revealed an increased frequency of Sub G1 DNA containing-cells in wells coated with fibronectin or collagen I at low densities and exposed to cilengitide, consistent with detachment-induced death (Table 1) [40].
###end p 39
###begin title 40
Cilengitide interferes with HUVEC adhesion on low-density beta1 integrin substrates.
###end title 40
###begin p 41
(a) HUVEC short-term adhesion assays performed on vitronectin (alphaVbeta3 ligand), fibronectin (alpha5beta1>alphaVbeta3 ligand) and collagen I (alpha1beta1/alpha2beta1 ligand) coated at the indicated concentrations, in medium only (black bars) or in the presence of EMD135981 (gray bars) or cilengitide (white bars). On vitronectin, cilengitide inhibited adhesion at all coating concentrations while on fibronectin and collagen I it blocked adhesion only at low coating concentrations. (n = 5). (b) HUVEC detachment assays. HUVEC were cultured for 18 hours on vitronectin, fibronectin or collagen I coated at the indicated concentrations, to allow for full attachment, before exposure for 4 hours to medium only (black bars), EMD135981 (gray bars) or cilengitide (white bars). Cilengitide detached HUVEC cultured on vitronectin at all coating concentrations, while it induced HUVEC detachment from fibronectin and collagen only at low coating concentrations (Triplicate wells/condition, n = 3). (c) HUVEC short-term adhesion assays performed on fibronectin and collagen I coated at the indicated concentrations, in medium only (black bars), in the presence of CGP77675 (white bars), cilengitide (gray bars), cilengitide+CGP77675 (hatched bars). Src inhibition did not prevent cilengitide-induced inhibition of cell adhesion on low matrix concentrations. (Triplicate wells/condition, n = 2). Attached cells were quantified by Crystal Violet staining and OD determination at 540 nm wavelength. Asterisks indicate statistical significant differences of the values relative to untreated controls (p<0.05).
###end p 41
###begin title 42
Relative cell death of HUVEC cultures exposed to cilengitide or EMD135981.
###end title 42
###begin p 43
HUVEC were cultured for 18 hours on vitronectin (alphaVbeta3 ligand), fibronectin (alpha5beta1>alphaVbeta3 ligand) and collagen I (alpha1beta1 and alpha2beta1 ligand) before they were exposed for 4 hours to EMD135981 or cilengitide. Cells were collected and Sub-G1 DNA content determined by propidium iodide staining and flow cytometry analysis. Results are expressed as percent increase of cell death relative to untreated conditions. Cilengitide increased HUVEC cell death on vitronectin at high and low protein coating concentrations, while on fibronectin and collagen it only did it at low protein coating concentrations. (n = 3).
###end p 43
###begin p 44
Taken together, these results demonstrate that cilengitide interferes with beta1-mediated adhesion under conditions of limited beta1-substrate concentration and limited beta1 engagement. This effect is independent of Src activity and is consistent with a beta3 to beta1 transdominant negative effect.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 302 305 288 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Smith1">[5]</xref>
###xml 307 311 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Maubant1">[40]</xref>
###xml 555 558 485 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
###xml 1111 1114 1024 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 1123 1126 1036 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 1132 1139 1045 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576/577</sup>
###xml 1159 1162 1072 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 1168 1171 1081 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 1595 1603 1505 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g009">Figure 9</xref>
The antiangiogenic activity of cilengitide is largely attributed to its ability to directly interfere with alphaVbeta3/alphaVbeta5-mediated adhesion of angiogenic endothelial cells, thereby inducing cell detachment-mediated death (anoikis) of cells relying on these integrins for adhesion and survival [5], [40]. Angiogenic endothelial cells, however, in addition to alphaVbeta3 and alphaVbeta5, express other integrins, in particular alpha1beta1, alpha2beta1, alpha4beta1, alpha5beta1, alpha6beta1, and alpha6beta4, which are not targeted by cilengitide [3]. Based on the current model of action of cilengitide, endothelial cells expressing and using these integrins would be insensitive to cilengitide effects. The present work was initiated to test whether endothelial cells expressing alphaVbeta3, but predominantly using beta1 integrins for adhesion, are insensitive to cilengitide, or whether they may indeed show some effects. Here we report five effects of cilengitide under such conditions: i) affinity maturation of alphaVbeta3 and its accumulation to the cell periphery; ii) phosphorylation of Src (Y419), FAK (Y397 and Y576/577) and VE-cadherin (Y658 and Y731); iii) disappearance of VE-cadherin from cell-cell contacts; iv) detachment of HUVEC cultured on low-density beta1 substrates; v) increased HUVEC monolayer permeability. These findings unravel a more complex picture of the mechanistic effects of cilengitide on endothelial cells and, more generally, highlight the role of integrins and integrin-induced signaling events in the regulation of endothelial cell functions (See Figure 9 for a working model).
###end p 46
###begin title 47
Proposed model of cilengitide effects on endothelial cells.
###end title 47
###begin p 48
Cilengitide acts on alphaVbeta3-expressing endothelial cells in three ways: 1, it suppresses alphaVbeta3-dependent adhesion by directly inhibiting alphaVbeta3-ligand-binding function; 2, it interferes with beta1 integrin-mediated cell adhesion through a transdominant negative effect induced by activated alphaVbeta3; 3, it stimulates phosphorylation of VE-cadherin cytoplasmic domain and disrupts VE-cadherin localization at cell-cell contacts through activation of alphaVbeta3 and Src-dependent signaling. Abbreviations: ECM, extracellular matrix; RGDfV, cilengitide; TDNE, transdominant negative effect; pp, phosphorylation.
###end p 48
###begin p 49
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Xiong1">[41]</xref>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Takagi1">[42]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Watson1">[43]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Umesh1">[44]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Tatone1">[45]</xref>
###xml 1566 1570 1535 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-AriasSalgado1">[46]</xref>
###xml 1835 1838 1793 1796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
###xml 2277 2280 2214 2217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 2286 2289 2223 2226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 2410 2414 2344 2348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Wang1">[26]</xref>
###xml 2416 2420 2350 2354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Potter1">[35]</xref>
There is structural evidence that high affinity RGD-based cyclopeptides, including cilengitide, can induce large-scale conformational changes of soluble truncated integrins consistent with ligand-induced activation [41], [42]. RGD-based soluble ligands were shown to induce some signaling events, such as intracellular calcium mobilization in neurons, smooth muscle cells and T lymphocytes [43], [44], or protein kinase C activation in oocytes [45]. Our work extends these findings by demonstrating that a monomeric, high-affinity RGD-based ligand induces affinity maturation (e.g. activation) of cell surface alphaVbeta3 leading to Src, FAK and VE-cadherin phosphorylation. The mechanism by which cilengitide elicits these signaling events remain to be determined. Current knowledge implies integrin clustering induced by immobilized or soluble-multivalent ligands as an essential step to recruit adaptor proteins or kinases and initiate signaling events. Our results demonstrate that a monovalent high-affinity ligand is nevertheless sufficient to elicit some signaling events. A plausible explanation is that since Src is constitutively associated with the cytoplasmic domain of the beta3 subunit, cilengitide-induced alphaVbeta3 'outside-in' activation and unclasping of the alphaVbeta3 cytoplasmic domains is sufficient to activate Src. Active Src can then complex with FAK resulting in mutual Src-FAK phosphorylation promoting lateral association of cilengitide-occupied alphaVbeta3 through its SH3 domain, resulting in patches formation at the cell periphery [46]. alphaVbeta3 activation by cilengitide, however, appears insufficient to fully activate downstream signaling pathways, such as ERK1/2, NF- kappaB or PI3K/Akt probably due to the lack of additional adaptor and signaling proteins normally present at focal adhesions [3]. The mutually exclusive localization of alphaVbeta3 and VE-cadherin at cellular junctions in confluent HUVEC suggests that a causal link between cilengitide-induced alphaVbeta3 and Src activation and the disappearance of VE-cadherin from cell-cell contacts. In our model activated alphaVbeta3 recruiting at cell-cell junctions brings active Src to VE-cadherin-catenin complexes, thereby promoting VE-cadherin phosphorylation at residues Y658 and Y731, dissociation from beta- and p120 catenins and disappearance from cell-cell contacts, consistent with published results [26], [35].
###end p 49
###begin p 50
###xml 1119 1123 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Wu1">[47]</xref>
###xml 1125 1129 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Qiao1">[48]</xref>
###xml 1427 1431 1407 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Ma1">[49]</xref>
The observed increased permeability induced by cilengitide is consistent with phosphorylation of VE-cadherin and disappearance from cell-cell contacts. However, in contrast to phosphorylation and displacement of VE-cadherin, which could be effectively prevented by pharmacological inhibition of Src, cilengitide-induced permeability was only partially prevented by Src inhibition. This partial effect of CGP77675 is likely due to the fact that cilengitide-ligated and activated alphaVbeta3 exerts a transdominant negative on beta1 integrins insensitive to Src inhibition. On low matrix densities the transdominant negative effect results in decreased cell adhesion and increased cell detachment. On high-matrix densities the same effect is insufficient to detach cells, but might cause cellular retraction as observed at early time points (5-30 minutes after addition of cilengitide) in HUVEC cultured on plastic wells or partial cell detachment as observed for HUVEC cultured on filters at the end of the permeability assays. Although a role for integrins in controlling vascular permeability has been proposed before [47], [48], the molecular mechanisms involved remained elusive. Of interest, in a recent report the extracellular matrix protein betaig-h3/TGFBI was shown to increase vascular permeability in a Src-dependent manner by binding to alphaVbeta5 and causing dissociation of VE-cadherin from endothelial junctions [49]. Taken together our report extends these observations, by demonstrating cilengitide-induced increased vascular permeability of HUVEC monolayers though combined Src-dependent disruption of VE-cadherin localization at cell-cell contacts, and Src-independent cell retraction consistent with a transdominant negative effect on beta1 integrins.
###end p 50
###begin p 51
###xml 344 348 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Ruegg1">[37]</xref>
###xml 371 378 350 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 598 602 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Eliceiri1">[50]</xref>
###xml 802 805 760 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Alghisi1">[3]</xref>
###xml 1112 1116 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Zaric1">[23]</xref>
###xml 1892 1896 1850 1854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Stupp1">[21]</xref>
These observations raise a number of questions that need to be addressed in future studies. One question relates to the potential role of alphaVbeta5 (the second integrin targeted by cilengitide) in these effects. On HUVEC, alphaVbeta5 is likely not to play a significant role since it is expressed at much lower levels compared to alphaVbeta3 [37] (and data not shown). In vivo, however, the situation might be different as alphaVbeta5 is also highly expressed on angiogenic endothelia and its ligation was shown to promote increased vascular permeability in response to angiogenic growth factors [50]. A second question relates to the mechanism of Src activation by cilengitide-bound alphaVbeta3, and the contribution of the alpha and beta subunit cytoplasmic domains since both domains can bind Src [3]. Another question relates to the role that soluble high-affinity ligands binding to non matrix-ligated integrins might exert on endothelial cell functions. In this perspective, this work extends previous observations demonstrating that soluble integrins ligand can induce COX-2 mRNA and protein expression [23]. This is of particular interest, since many circulating plasma proteins are natural integrin ligands (e.g. fibronectin, vitronectin, fibrinogen) and their binding to luminal integrins (i.e. not engaged in cell-matrix adhesion) may elicit important, yet largely uncharacterized, regulatory signals. A last important question is whether the permeability-promoting effect of cilengitide observed in this study may have therapeutic implications. Cilengitide is currently in clinical development in oncology. Phase I and II clinical studies have demonstrated that it is well tolerated (no dose-limiting toxicities were observed) and provided initial evidence of activity. Phase III studies in combination with chemotherapy and radiotherapy are underway in glioblastoma multiforme [21]. Cilengitide might be a particularly well-suited drug to combine with chemotherapeutic agents with the purpose to improve chemotherapy delivery to tumors, which is one of the limiting events in cancer therapies.
###end p 51
###begin title 52
Materials and Methods
###end title 52
###begin title 53
Cells and culture media, antibodies and reagents
###end title 53
###begin p 54
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cells and culture media</italic>
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Ruegg1">[37]</xref>
###xml 132 142 132 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Antibodies</italic>
###xml 161 168 161 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">576/577</sup>
###xml 294 297 294 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">419</sup>
###xml 310 313 310 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">529</sup>
###xml 456 459 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">658</sup>
###xml 482 485 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">731</sup>
###xml 1084 1092 1053 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Reagents</italic>
Cells and culture media: HUVEC cells were prepared and cultured as described previously [37] and were used between passage 3 and 5. Antibodies: anti-FAK, anti-pY576/577FAK, anti-Src, anti-ERK1/2 and anti-phospho ERK1/2 antibodies were from Cell Signaling Technology, Inc. (Danvers, MA); anti-pY419Src, anti- pY529Src were from Sigma Aldrich (St. Louis, MO); anti-VE-cadherin mAb was from BD Transduction Laboratoriestrade mark (Franklin Lakes, NJ), anti-pY658VE-cadherin and anti-pY731VE-cadherin antibodies were from Biosource International, Inc. (Camarillo, CA), anti-beta3 clone Ab1932, anti-alphaVbeta3 (mAb, clone LM609) and anti-total-beta1 were from Chemicon (Temecula, CA, USA). The anti-beta3 mAb clone AP-3 was obtained from Dr. T.J. Kunicki, the Scripps Research Institute (La Jolla, CA). The anti-beta3 ligand-induced binding site mAbs were kindly provided by Dr. M. Ginsberg (LIBS-1), University of California San Diego (La Jolla, CA) or purchased from Abcam Inc. (CRC54), Cambridge (MA USA). Anti-beta1 LIBS (HUTS-21) was from BD Biosciences Pharmingen (San Diego, CA), Reagents: BSA, fibronectin, collagen I, vitronectin and Cristal Violet were from Sigma-Aldrich, Buchs, Switzerland. Collagen I (PureCol(R)) was from Nutacon BV, Leimuiden, The Netherlands. The EMD121974 (the inner salt form of cyclic-(Arg-Gly-Asp-[D-Phe]-[N-Me-Val]) and EMD135981 (the inner salt form of cyclic-(Arg-[ss-Ala]-Asp-[D-Phe]-Val) cyclopeptides were synthesized by Dr A. Jonczyk, Merck KGaA, Darmstadt, Germany. The Src inhibitor CGP77675 was provided by Dr. D. Fabbro, Novartis AG (Basel, Switzerland), VEGF was purchased from R&D Systems (Abingdon, UK).
###end p 54
###begin title 55
FACS analysis
###end title 55
###begin p 56
HUVEC were collected by trypsinization, washed twice in PBS/5% FCS and incubated with relevant primary antibodies for 30 minutes at 4degreesC. After washing in cold PBS, cells were incubated with a secondary PE-labeled antibody for 30 minutes at 4degreesC. Cells were washed and analyzed with a FACScan II(R) and Cell Quest(R) software (Becton Dickinson, Mountain View, California).
###end p 56
###begin title 57
Immunofluorescence microscopy
###end title 57
###begin p 58
HUVEC cells were cultured subconfluent or at confluency on glass coverslips pre-coated with fibronectin (3 mg/ml) or collagen I (1 mg/ml) placed in 12 well plates in complete M199 medium. After 16 hours, cultures were stimulated with cilengitide or EMD135981 (10 microM each) or VEGF (100 ng/ml) for 20 minutes, or otherwise at the indicated times. To inhibit Src, CGP77675 (2.5 microM) was added 15 minutes before addition of cilengitide. Cultures were then immediately fixed in 4% PFA for 10 minutes at room temperature, permeabilized with 0.1% Triton X-100, blocked with 1% BSA and incubated for 1 hour with the relevant primary antibodies (5 microg/ml). After washing, cells were incubated with a Cy5 or FITC-conjugated secondary antibody. DAPI was used to counterstain nuclei. Stained cells were mounted in Prolong Antifade medium (Molecular Probes, Invitrogen) and viewed by epifluorescence microscopy (Axioplan with objective EC Plan Neofluar 40x/1.3 oil ph 3, Carl Zeiss AG, Zurich). Images were acquired with an Axiocam camera (Carl Zeiss AG) and the Axiovision program (release 4.7, Carl Zeiss AG) and processed (zooming, gamma and contrast adjustments) with Adobe Photoshop CS3 (Adobe Systems Inc. San Jose, CA)
###end p 58
###begin title 59
Quantification of VE-cadherin immunostaining
###end title 59
###begin p 60
###xml 841 843 833 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 944 953 936 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004449-g006">Figure 6b</xref>
Quantification of fluorescence of VE-cadherin staining was performed with the program Metamorph 7.5 (Molecular Devices, Downingtown, PA). Briefly, a program script was defined to draw a line region along the plasma membrane of each cell on the images (magnification 40x). Then, segment regions (i.e. squares of 2.4 micromx6.4 microm - lengthxwidth) were created along the line and, in each segment region, the fluorescence was measured according to a threshold defined from a negative control. The measured fluorescence average intensities were then normalized within each segment by multiplying the fluorescence average intensity by the ratio of the threshold area divided by the total area. These normalized intensities (NI) were then arbitrarily divided in two groups: group 0 for NI<5; group 1 for 5<NI, corresponding to absent or faint vs intense labeling, respectively. On each image these groups were counted and plotted as shown in the Figure 6b. Quantification was performed on 30 cells per conditions.
###end p 60
###begin title 61
SDS-PAGE and Western blotting
###end title 61
###begin p 62
HUVEC cells were treated with the different compounds as described in the text or figure legends. Total cell lysates (20 microl per lane) were resolved by 7.5% SDS-PAGE and blotted onto Immobilon-P membranes (Millipore, Volketswil, Switzerland). Membranes were blocked with 5% BSA prepared in 1x TBS-T. Primary antibodies were prepared as 1:2000 dilutions in 1x TBS-T with 3% BSA and added to the membrane overnight at 4degreesC. Phosphoproteins were always detected first prior stripping the membranes to detect total proteins. Membranes were then washed and processed for HRP-coupled secondary antibody according to standard laboratory protocols and the ECL system was used for detection (Amersham-Pharmacia Biotech, Dubendorf, Switzerland). Membranes were reprobed for actin to assess equal loading of the samples. To compare expression levels of the different proteins, revealed Western blots were scanned and band pixelization for total and phosphorylated proteins were analyzed with the AIDA bioimaging software (raytest Isotopenmessgeraete GmbH, Straubenhardt, Germany). The number of pixels of each individual phosphoprotein bands was normalized to the corresponding total protein band pixel numbers.
###end p 62
###begin title 63
Adhesion and detachment assays
###end title 63
###begin p 64
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1030 1031 1002 1003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
HUVEC were seeded in triplicate in 96-well plates (2x104 cells/well) pre-coated with graded amounts of vitronectin (1-0.1 microg/ml), fibronectin (3-0.1 microg/ml), collagen I (1-0.01 microg/ml). After coating, the wells were saturated with 1% BSA. For short-term adhesion assays, cells were seeded in serum-free medium in the absence or presence of 10 microM cilengitide or EMD135981 and adhesion quantified after 2 hours. For survival assays, the cells were seeded in complete media and left to adhere for 16 hours followed by a 3 hours starvation in serum-free medium before addition of 10 microM cilengitide or EMD135981 for another 2 hours. To inhibit Src, CGP77675 (2.5 microM) was added 15 minutes before addition of cilengitide. At the end of the assay period, cultures were rinsed with two gentle washes with PBS (with Ca/Mg), fixed for 15 minutes with 4% paraformaldehyde and stained for 15 minutes with 0.5% Crystal Violet. Stained wells were washed and CV was extracted with 100 microl CV distain solution (29.4 g/l Na3-citrate in 50% ethanol) and absorbance measured at 540 nm wavelength.
###end p 64
###begin title 65
Cell viability assay
###end title 65
###begin p 66
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Bezzi1">[51]</xref>
Sub-G1 DNA content assay was performed as described [51]. Briefly, HUVEC were collected as above, resuspended in 70% ice cold ethanol under vortex and incubated for 2 hours at -20degreesC. Cells were recovered by centrifugation and resuspended in PBS. 50 microg/ml RNase A (Roche, Basel) was added and samples were incubated at room temperature for 5 minutes before staining with propidium iodide (PI, 50 microg/ml) for 30 minutes at 37degreesC. Stained cells were analyzed with a FACScan II(R) and Cell Quest(R) software (Becton Dickinson, Mountain View, CA).
###end p 66
###begin title 67
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro permeability assay
###end title 67
###begin p 68
###xml 27 31 27 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Esser1">[52]</xref>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 595 599 575 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004449-Wong1">[53]</xref>
###xml 606 607 586 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</sub>
###xml 613 614 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
The assay was adapted from [52]. Briefly, HUVEC were seeded, in triplicate, at a density of 40x103 cells on polystyrene filter inserts (3 microm pore size, BD Biosciences, Basel, Switzerland, catalogue number 353096) pre-coated with fibronectin (3 microg/ml) or collagen I (1 microg/ml) or vitronectin (1 microg/ml), in 12-well plates in a total volume of 200 microl and 1 ml of complete M199 for the upper and lower chambers, respectively. After 20 hours, the medium in the upper chamber was gently exchanged with fresh one containing the paracellular permeability tracer molecule FITC-dextran [53] (av. Mr 40x103, Sigma-Aldrich, Basel, Switzerland, catalogue number FD40S, 0.5 mg/ml final concentration) and either nothing else (control), CGP77675 (final concentration 2.5 microM), cilengitide (final concentration 10 microM) or both compounds. CGP77675 (2.5 microM) was added 15 minutes before addition of cilengitide. At given time points, 50 microl aliquots from the lower chamber were removed for measurement and replaced with 50 microl of fresh medium in order to maintain the hydrostatic equilibrium. The fluorescence of each sample diluted (1:20) in PBS, was measured at 485/530 nm excitation/emission wavelengths. The zero time point (t = 0) was defined by diluting 50 microl (1:20) in PBS. After the last time point, wells were fixed with 100 microl 4% PFA, stained by Crystal Violet and photographed (Axiovert 40 CFL, Carl Zeiss AG, Zurich, Switzerland).
###end p 68
###begin title 69
Statistical analysis
###end title 69
###begin p 70
###xml 70 71 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 82 83 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Results are expressed as mean+/-s.d.. Data were analyzed by Student's t-test for. P values<0.05 were considered significant.
###end p 70
###begin p 71
We thank Drs A. Jonczyk, T.J. Kunicki, D. Fabbro and M. Ginsberg for providing reagents. Dr. S.L. Goodman is acknowledged for helpful discussion. We thank J-C. Sarria, BioImaging and Optics platform (BIOp), Faculty of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland, for help with the VE-cadherin quantitation. We thank Drs A. Mariotti and G. Lorusso for discussion and critical reading of the manuscript and R. Driscoll for editorial assistance.
###end p 71
###begin title 72
References
###end title 72
###begin article-title 73
Cell-matrix adhesion in vascular development.
###end article-title 73
###begin article-title 74
Integrins: bidirectional, allosteric signaling machines.
###end article-title 74
###begin article-title 75
Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets.
###end article-title 75
###begin article-title 76
Integrin alphavbeta3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis.
###end article-title 76
###begin article-title 77
Cilengitide Merck.
###end article-title 77
###begin article-title 78
N-Methylated cyclic RGD peptides as highly active and selective alphaVbeta3 integrin antagonists.
###end article-title 78
###begin article-title 79
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
###end article-title 79
###begin article-title 80
Inhibition of the alpha-V integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.
###end article-title 80
###begin article-title 81
###xml 88 97 <span type="species:ncbi:10090">nude mice</span>
Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
###end article-title 81
###begin article-title 82
###xml 58 63 <span type="species:ncbi:9606">human</span>
Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
###end article-title 82
###begin article-title 83
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 112 121 <span type="species:ncbi:10090">nude mice</span>
An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.
###end article-title 83
###begin article-title 84
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
###end article-title 84
###begin article-title 85
Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappaB activation and endothelial cell survival.
###end article-title 85
###begin article-title 86
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
###end article-title 86
###begin article-title 87
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
###end article-title 87
###begin article-title 88
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Assessment of the biological and pharmacological effects of the alpha V beta3 and alpha V beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
###end article-title 88
###begin article-title 89
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
###end article-title 89
###begin article-title 90
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
###end article-title 90
###begin article-title 91
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
###end article-title 91
###begin article-title 92
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.
###end article-title 92
###begin article-title 93
Integrin Inhibitors Reaching the Clinic.
###end article-title 93
###begin article-title 94
Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
###end article-title 94
###begin article-title 95
Integrin-mediated adhesion and soluble ligand cinding stabilize COX-2 protein levels in endothelial cells by Inducing expression and preventing degradation.
###end article-title 95
###begin article-title 96
Manganese-induced integrin affinity maturation promotes recruitment of alpha V beta 3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src.
###end article-title 96
###begin article-title 97
Endothelial cell-cell junctions: happy together.
###end article-title 97
###begin article-title 98
Integrins regulate VE-cadherin and catenins: Dependence of this regulation on Src, but not on Ras.
###end article-title 98
###begin article-title 99
Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins.
###end article-title 99
###begin article-title 100
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
###end article-title 100
###begin article-title 101
Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa.
###end article-title 101
###begin article-title 102
Crystal structures of c-Src reveal features of its autoinhibitory mechanism.
###end article-title 102
###begin article-title 103
The interplay between Src and integrins in normal and tumor biology.
###end article-title 103
###begin article-title 104
Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases.
###end article-title 104
###begin article-title 105
A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
###end article-title 105
###begin article-title 106
Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site.
###end article-title 106
###begin article-title 107
Tyrosine Phosphorylation of VE-cadherin Prevents Binding of p120- and beta-Catenin and Maintains the Cellular Mesenchymal State.
###end article-title 107
###begin article-title 108
The role of adherens junctions and VE-cadherin in the control of vascular permeability.
###end article-title 108
###begin article-title 109
Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-g.
###end article-title 109
###begin article-title 110
Trans-dominant inhibition of integrin function.
###end article-title 110
###begin article-title 111
Competition for talin results in trans-dominant inhibition of integrin activation.
###end article-title 111
###begin article-title 112
###xml 121 126 <span type="species:ncbi:9606">human</span>
Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
###end article-title 112
###begin article-title 113
Purification, analysis, and crystal structure of integrins.
###end article-title 113
###begin article-title 114
Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling.
###end article-title 114
###begin article-title 115
Integrin-binding RGD peptides induce rapid intracellular calcium increases and MAPK signaling in cortical neurons.
###end article-title 115
###begin article-title 116
Integrin ligands mobilize Ca2+ from ryanodine receptor-gated stores and lysosome-related acidic organelles in pulmonary arterial smooth muscle cells.
###end article-title 116
###begin article-title 117
###xml 187 192 <span type="species:ncbi:10090">mouse</span>
Possible involvement of integrin-mediated signalling in oocyte activation: evidence that a cyclic RGD-containing peptide can stimulate protein kinase C and cortical granule exocytosis in mouse oocytes.
###end article-title 117
###begin article-title 118
Src kinase activation by direct interaction with the integrin beta cytoplasmic domain.
###end article-title 118
###begin article-title 119
Integrin binding to fibronectin and vitronectin maintains the barrier function of isolated porcine coronary venules.
###end article-title 119
###begin article-title 120
Arg-Gly-Asp peptide increases endothelial hydraulic conductivity: comparison with thrombin response.
###end article-title 120
###begin article-title 121
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation.
###end article-title 121
###begin article-title 122
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling.
###end article-title 122
###begin article-title 123
Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Ak.
###end article-title 123
###begin article-title 124
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells.
###end article-title 124
###begin article-title 125
A Synthetic Peptide Corresponding to the Extracellular Domain of Occludin Perturbs the Tight Junction Permeability Barrier.
###end article-title 125
###begin p 126
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 126
###begin p 127
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from Oncosuisse (OCS 0181212-12-2005 and 02020.02.2007), the National Center for Competence in Research (NCCR, molecular Oncology, a research instrument of the SNF), and the Medic Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 127

